Ken Griffin Shattuck Labs, Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.0 - $4.85 $22,500 - $36,375	-7,500 Reduced 86.21%	1,200 $4,000
Q2 2024 Aug 14, 2024	SELL	$3.56 - $11.18 $28,480 - $89,440	-8,000 Reduced 47.9%	8,700 $33,000
Q1 2024 May 15, 2024	BUY	$7.37 - $10.09 $16,951 - $23,207	2,300 Added 15.97%	16,700 $149,000
Q4 2023 Feb 14, 2024	BUY	$1.37 - $7.24 $19,043 - $100,636	13,900 Added 2780.0%	14,400 $102,000
Q3 2023 Nov 14, 2023	BUY	$1.42 - $3.16 $710 - $1,580	500 New	500 $0

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.